TITLE

Canaccord Grabs Jefferies Cleantech Head

AUTHOR(S)
Rozens, Aleksandrs
PUB. DATE
February 2011
SOURCE
Mergers & Acquisitions Report;2/28/2011, Vol. 24 Issue 9, p5
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article announces the appointment of Jeffrey Lipton as managing director for the investment banking team covering the sustainability and cleantech sector at Canaccord Genuity Inc.
ACCESSION #
59152539

 

Related Articles

  • DexCom sells 4.7M shares in underwriting agreement.  // Medical Device Daily;5/6/2011, Vol. 15 Issue 88, p2 

    The article discusses an underwriting agreement between Canaccord Genuity and DexCom which sold 4.7 million shares of the latter.

  • Analyst Sees 'Record Launch Activity'.  // Chain Drug Review;4/23/2012, Vol. 34 Issue 8, p238 

    The article presents information on a report by an analyst Randall Stanicky from Canaccord Genuity Corp., according to which there will be a tremendous growth of the generic drug markets in the U.S. by 2020 which will lead to huge impact on brands' prescriptions and sales.

  • Lipton to receive Palladium Medal. Chang, Joseph // ICIS Chemical Business Americas;1/15/2007, Vol. 271 Issue 2, p7 

    The article announces that Jeffrey Lipton, president of Nova Chemicals, will receive the 2007 International Palladium Award from the Societe de Chimie Industrielle.

  • Nova seeks new chief for styrenics business. Esposito, Frank // Plastics News;1/24/2000, Vol. 11 Issue 49, p9 

    Reports on Nova Chemicals Inc.'s search for a new vice president for its styrenics business. Nova President and Chief Executive Officer Jeffrey Lipton's take over as vice president of the business; Lipton's replacement of Wes Lucas; Division's posting of a loss of $2 million.

  • Investors' hearts racing at cardio company presentations. HAIMOVITCH, LARRY // Medical Device Daily;12/13/2010, Vol. 14 Issue 240, p1 

    The article discusses the highlights of the 2010 Canaccord Genuity Cardiovascular Conference in San Francisco, California. The event featured private companies addressing the cardiovascular device markets. Vascular site access closure posted an estimated global revenue in 2010 of 600 million...

  • Financings roundup.  // Medical Device Daily;8/18/2010, Vol. 14 Issue 160, p2 

    The article reports that Delcath has sold more than 5 million shares of its common stock with Canaccord Genuity as its bookrunner, to fund its clinical trials, research and commercialization of its products.

  • Nova CEO Lipton Sees Powerful Peak for Plastics. Chang, Joseph // Chemical Market Reporter;9/22/2003, Vol. 264 Issue 9, p3 

    Reports on the views of Jeffrey Lipton, the president of Nova Chemicals Corp. for the plastics market in the U.S. Forecast of the peak for global polyethylene; Importance of the balance of chemical products; Improvement of the business of the chemical sector.

  • Momenta Seeks to Raise $57M to Fund Follow-on Biologics. Powers, Marie // BioWorld Today;12/9/2010, Vol. 21 Issue 237, p1 

    The article reports on Momenta Pharmaceuticals Incorporated's offering of four million shares of its common stock. The proceeds is approximated at 75.4 million U.S. dollars. UBS Investment Bank is the sole book-running manager for the offering while Cowen and Canaccord are the co-managers. Duane...

  • Cytokinetics Shares Drop 22% Despite 'Encouraging' Data.  // BioWorld Today;12/14/2010, Vol. 21 Issue 240, p3 

    The article reports on a drop in the shares of Cytokinetics on December 13, 2010 despite positive results in amyotrophic lateral sclerosis (ALS) patients from a trial of CK-2017357, a fast skeletal muscle troponin activator and drug candidate of the company. The company plans to proceed with a...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics